These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 22156047)

  • 21. Sugar-based peptidomimetics inhibit amyloid β-peptide aggregation.
    Dorgeret B; Khemtémourian L; Correia I; Soulier JL; Lequin O; Ongeri S
    Eur J Med Chem; 2011 Dec; 46(12):5959-69. PubMed ID: 22027101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of Aβ (1-40) and Aβ (1-42) monomer and fibrils by capillary electrophoresis.
    Picou RA; Kheterpal I; Wellman AD; Minnamreddy M; Ku G; Gilman SD
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Mar; 879(9-10):627-32. PubMed ID: 21334989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ex situ atomic force microscopy analysis of beta-amyloid self-assembly and deposition on a synthetic template.
    Ha C; Park CB
    Langmuir; 2006 Aug; 22(16):6977-85. PubMed ID: 16863248
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amyloid-β: the seeds of darkness.
    Fodero-Tavoletti MT; Villemagne VL; Rowe CC; Masters CL; Barnham KJ; Cappai R
    Int J Biochem Cell Biol; 2011 Sep; 43(9):1247-51. PubMed ID: 21601003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single point mutations induce a switch in the molecular mechanism of the aggregation of the Alzheimer's disease associated Aβ42 peptide.
    Bolognesi B; Cohen SI; Aran Terol P; Esbjörner EK; Giorgetti S; Mossuto MF; Natalello A; Brorsson AC; Knowles TP; Dobson CM; Luheshi LM
    ACS Chem Biol; 2014 Feb; 9(2):378-82. PubMed ID: 24199868
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Applications of AFM in mechanism study of Alzheimer's disease].
    Wang J; Yang T; Wang D
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2007 Dec; 24(6):1428-31. PubMed ID: 18232509
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease.
    Golde TE; Eckman CB; Younkin SG
    Biochim Biophys Acta; 2000 Jul; 1502(1):172-87. PubMed ID: 10899442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-n oligomers as therapeutic targets of Alzheimer's disease.
    Ono K; Yamada M
    J Neurochem; 2011 Apr; 117(1):19-28. PubMed ID: 21244429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human lysozyme inhibits the in vitro aggregation of Aβ peptides, which in vivo are associated with Alzheimer's disease.
    Luo J; Wärmländer SK; Gräslund A; Abrahams JP
    Chem Commun (Camb); 2013 Jul; 49(58):6507-9. PubMed ID: 23764522
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phosphorus dendrimers affect Alzheimer's (Aβ1-28) peptide and MAP-Tau protein aggregation.
    Wasiak T; Ionov M; Nieznanski K; Nieznanska H; Klementieva O; Granell M; Cladera J; Majoral JP; Caminade AM; Klajnert B
    Mol Pharm; 2012 Mar; 9(3):458-69. PubMed ID: 22206488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High ability of apolipoprotein E4 to stabilize amyloid-β peptide oligomers, the pathological entities responsible for Alzheimer's disease.
    Cerf E; Gustot A; Goormaghtigh E; Ruysschaert JM; Raussens V
    FASEB J; 2011 May; 25(5):1585-95. PubMed ID: 21266538
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid assembly of amyloid-beta peptide at a liquid/liquid interface produces unstable beta-sheet fibers.
    Nichols MR; Moss MA; Reed DK; Hoh JH; Rosenberry TL
    Biochemistry; 2005 Jan; 44(1):165-73. PubMed ID: 15628857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bacterial inclusion bodies of Alzheimer's disease β-amyloid peptides can be employed to study native-like aggregation intermediate states.
    Dasari M; Espargaro A; Sabate R; Lopez del Amo JM; Fink U; Grelle G; Bieschke J; Ventura S; Reif B
    Chembiochem; 2011 Feb; 12(3):407-23. PubMed ID: 21290543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A strategy for designing a peptide probe for detection of β-amyloid oligomers.
    Hu Y; Su B; Kim CS; Hernandez M; Rostagno A; Ghiso J; Kim JR
    Chembiochem; 2010 Nov; 11(17):2409-18. PubMed ID: 21031399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pyroglutamate-Aβ: role in the natural history of Alzheimer's disease.
    Gunn AP; Masters CL; Cherny RA
    Int J Biochem Cell Biol; 2010 Dec; 42(12):1915-8. PubMed ID: 20833262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intracellular amyloid-β accumulation in calcium-binding protein-deficient neurons leads to amyloid-β plaque formation in animal model of Alzheimer's disease.
    Moon M; Hong HS; Nam DW; Baik SH; Song H; Kook SY; Kim YS; Lee J; Mook-Jung I
    J Alzheimers Dis; 2012; 29(3):615-28. PubMed ID: 22269161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Specific binding of a β-cyclodextrin dimer to the amyloid β peptide modulates the peptide aggregation process.
    Wahlström A; Cukalevski R; Danielsson J; Jarvet J; Onagi H; Rebek J; Linse S; Gräslund A
    Biochemistry; 2012 May; 51(21):4280-9. PubMed ID: 22554145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structural, morphological, and kinetic studies of β-amyloid peptide aggregation on self-assembled monolayers.
    Wang Q; Shah N; Zhao J; Wang C; Zhao C; Liu L; Li L; Zhou F; Zheng J
    Phys Chem Chem Phys; 2011 Sep; 13(33):15200-10. PubMed ID: 21769359
    [TBL] [Abstract][Full Text] [Related]  

  • 39. I32E and V36K double mutation in beta2-sheet abrogates amyloid beta peptide toxicity.
    Subramanian S; Mishra PK; Bandopadhyay D
    Indian J Exp Biol; 2010 Nov; 48(11):1098-102. PubMed ID: 21117449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice.
    Oddo S; Caccamo A; Cheng D; Jouleh B; Torp R; LaFerla FM
    J Neurochem; 2007 Aug; 102(4):1053-63. PubMed ID: 17472708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.